Human cord blood applications in cell therapy: Looking back and look ahead

Expert Opinion on Biological Therapy

Volumn 12, Issue 8, 2012, Pages 1059-1066

  Zhou, Hongyan ^a   Chang, Stephen ^a   Rao, Mahendra ^b  

^a New York Stem Cell Foundation   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

clinical application; cord blood; GMP; regenerative medicine; reprogramming; transplantation

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA; AUTOMATION; CELL FUNCTION; CELL THERAPY; CELL VIABILITY; CEREBRAL PALSY; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; FEEDER CELL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEARING LOSS; HEART INFARCTION; HLA MATCHING; HUMAN; HUNTINGTON CHOREA; IMMUNE DEFICIENCY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKEMIA; METABOLIC DISORDER; MORTALITY; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; THROMBOCYTE COUNT; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

BIOLOGICAL SPECIMEN BANKS; BIOTECHNOLOGY; CELL DIFFERENTIATION; CELL PROLIFERATION; CORD BLOOD STEM CELL TRANSPLANTATION; FORECASTING; GUIDELINES AS TOPIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; REGENERATION; REGENERATIVE MEDICINE;

HARNESS; IPS;

EID: 84863802660     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.691161     Document Type: Review

References (50)

1. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-8
2. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828-32
3. Ortiz-Gonzalez XR, Keene CD, Verfaillie CM, Low WC. Neural induction of adult bone marrow and umbilical cord stem cells. Curr Neurovasc Res 2004;1:207-13
4. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72
5. Beatty PG, Boucher KM, Mori M, Milford EL. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol 2000;61:834-40
6. Barker JN, Davies SM, DeFor T, et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: Results of a matched-pair analysis. Blood 2001;97:2957-61
7. Vilmer E, Sterkers G, Rahimy C, et al. HLA-mismatched cord-blood transplantation in a patient with advanced leukemia. Transplantation 1992;53:1155-7
8. Gluckman E, Ruggeri A, Rocha V, et al. Family-directed umbilical cord blood banking. Haematologica 2011;96:1700-7
9. Ballen KK. New trends in umbilical cord blood transplantation. Blood 2005;105:3786-92
10. Petropoulou AD, Rocha V. Risk factors and options to improve engraftment in unrelated cord blood transplantation. Stem Cells Int 2011;2011:610514
11. Laughlin MJ, Eapen M, Rubinstein Pet al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351:2265-75
12. Cohen Y, Nagler A. Umbilical cord blood transplantation-how, when and for whom? Blood Rev 2004;18:167-79
13. Avery S, Barker JN. Cord blood transplants: One, two or more units? Curr Opin Hematol 2010;17:531-7
14. Reinisch A, Bartmann C, Rohde E, et al. Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen Med 2007;2:371-82
15. Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: A phase I/II study. Lancet Oncol 2008;9:831-9
16. Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011;118:6438-45
17. Harris DT, Rogers I. Umbilical cord blood: A unique source of pluripotent stem cells for regenerative medicine. Curr Stem Cell Res Ther 2007;2:301-9
18. Yoshida S, Ishikawa F, Kawano N, et al. Human cord blood-derived cells generate insulin-producing cells in vivo. Stem Cells 2005;23:1409-16
19. Ende N, Chen R, Reddi AS. Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochem Biophys Res Commun 2004;325:665-9
20. Haller MJ, Viener HL, Wasserfall C, et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 2008;36:710-15
21. Haller MJ, Wasserfall CH, McGrail KM, et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 2009;32:2041-6
22. Zhao Y, Lin B, Darflinger R, et al. Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One 2009;4:e4226
23. Greco N, Laughlin MJ. Umbilical cord blood stem cells for myocardial repair and regeneration. Methods Mol Biol 2010;660:29-52
24. Boltze J, Schmidt UR, Reich DM, et al. Determination of the therapeutic time window for human umbilical cord blood mononuclear cell transplantation following experimental stroke in rats. Cell Transplant 2011Available from: Http://www.ncbi. nlm.nih.gov/pubmed/22182968
25. Garbuzova-Davis S, Willing AE, Zigova Tet al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: Distribution, migration, and differentiation. J Hematother Stem Cell Res 2003;12:255-70
26. Kaner T, Karadag T, Cirak B, et al. The effects of human umbilical cord blood transplantation in rats with experimentally induced spinal cord injury. J Neurosurg Spine 2010;13:543-51
27. Haase A, Olmer R, Schwanke K, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009;5:434-41
28. Hu K, Yu J, Suknuntha K, et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 2011;117:e109-19
29. Ye Z, Liu CF, Jang YY. Hematopoietic cells as sources for patient-specific iPSCs and disease modeling. Cell Cycle 2011;10:2840-4
30. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 2011;117:4773-7
31. Giorgetti A, Montserrat N, Aasen T, et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 2009;5:353-7
32. Narsinh KH, Wu JC. Gene correction in human embryonic and induced] pluripotent stem cells: Promises and challenges ahead. Mol Ther 2010;18:1061-3
33. Kazuki Y, Hiratsuka M, Takiguchi M, et al. Complete genetic correction of ips cells from duchenne muscular dystrophy. Mol Ther 2009;18:386-93
34. Ye Z, Zhan H, Mali P, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009;114:5473-80
35. Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA 2011;108:14234-9
36. Meng X, Neises A, Su RJ, et al. Efficient reprogramming of human cord blood CD34(+) cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther 2012;20:408-16
37. Rodriguez-Piza I, Richaud-Patin Y, Vassena R, et al. Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. Stem Cells 2009;28:36-44
38. Vallier L, Alexander M, Pedersen RA. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 2005;118:4495-509
39. Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006;24:185-7
40. Zhou H, Ding S. Evolution of induced pluripotent stem cell technology. Curr Opin Hematol 2010;17:276-80
41. Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci USA 2009;106:15720-5
42. Crook JM, Peura TT, Kravets L, et al. The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell 2007;1:490-4
43. Bock C, Kiskinis E, Verstappen G, et al. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011;144:439-52
44. Querol S, Mufti GJ, Marsh SG, et al. Cord blood stem cells for hematopoietic stem cell transplantation in the UK: How big should the bank be? Haematologica 2009;94:536-41
45. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol 2008;26:739-40
46. Pedron B, Duval M, Elbou OM, et al. Common genomic HLA haplotypes contributing to successful donor search in unrelated hematopoietic transplantation. Bone Marrow Transplant 2003;31:423-7
47. Broxmeyer HE. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell 2010;6:21-4
48. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009;5:111-23
49. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009;41:1350-3
50. Hu BY, Weick JP, Yu J, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci USA 2010;107:4335-40